Image_2_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.jpeg
Breast cancer (BC) is the most common tumor to develop cutaneous metastases. Most BCs with cutaneous metastasis are human epidermal growth factor receptor 2 (HER2)-positive subtypes. Although the molecular mechanisms of breast cancer metastasis to different sites and the corresponding treatment methods are areas of in-depth research, there are few studies on cutaneous metastasis.
Case PresentationFive HER2-positive BC patients with extensive cutaneous metastases were treated with a regimen containing pyrotinib, a novel small-molecule tyrosine kinase inhibitor that irreversibly blocks epidermal growth factor receptor (EGFR), HER2, and human epidermal growth factor receptor 4 (HER4), then their cutaneous metastases quickly resolved at an astonishing speed and their condition was well controlled during the follow-up period.
ConclusionsThis case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. Based on this, we recommend that pyrotinib can be used as a supplement to trastuzumab for HER2-positive BC patients with cutaneous metastases. In addition, we should consider that the pan-inhibitory effect of pyrotinib on EGFR, HER2, and HER4 may provide a dual therapeutic effect against HER2 and mucin 1.
History
References
- https://doi.org//10.1159/000331417
- https://doi.org//10.1186/bcr2944
- https://doi.org//10.1016/0190-9622(93)70173-q
- https://doi.org//10.1111/j.1365-4632.2012.05635.x
- https://doi.org//10.1111/tbj.14049
- https://doi.org//10.1111/exd.14221
- https://doi.org//10.1155/2012/937253
- https://doi.org//10.1038/74704
- https://doi.org//10.1158/0008-5472.Can-07-2068
- https://doi.org//10.1158/0008-5472.Can-08-4597
- https://doi.org//10.3892/ol.2014.2594
- https://doi.org//10.1700/1334.14821
- https://doi.org//10.1097/md.0000000000009981
- https://doi.org//10.4143/crt.2014.46.2.194
- https://doi.org//10.3390/cancers11060737
- https://doi.org//10.1042/BSR20194167
- https://doi.org//10.1016/j.cellimm.2017.07.005
- https://doi.org//10.1097/md.0000000000020809
- https://doi.org//10.1097/md.0000000000023406
- https://doi.org//10.21037/apm-20-1363
- https://doi.org//10.2147/ott.S252117
- https://doi.org//10.2147/ott.S289876
- https://doi.org//10.1111/1759-7714.13480
- https://doi.org//10.3389/fonc.2020.559057
- https://doi.org//10.3389/fonc.2019.01453
- https://doi.org//10.1042/bsr20194167
- https://doi.org//10.2147/cmar.S281765
- https://doi.org//10.1111/1759-7714.13889
- https://doi.org//10.2147/ott.S286024
- https://doi.org//10.1159/000468521
- https://doi.org//10.1023/B%3ADRUG.0000047104.45929.ea
- https://doi.org//10.1200/jco.19.00108
- https://doi.org//10.3727/096504020x15960154585410
- https://doi.org//10.1038/onc.2008.432
- https://doi.org//10.1001/jamaoncol.2015.0830
- https://doi.org//10.1158/0008-5472.Can-09-3321
- https://doi.org//10.1016/j.clbc.2013.04.001
- https://doi.org//10.1016/j.ejca.2007.08.018
- https://doi.org//10.1158/1078-0432.Ccr-17-3250
- https://doi.org//10.1007/s10549-011-1572-5
- https://doi.org//10.1093/annonc/mdr484
- https://doi.org//10.1016/j.semcancer.2019.08.012
- https://doi.org//10.3390/ijms20092272
- https://doi.org//10.1186/s13058-015-0558-3
- https://doi.org//10.1016/j.addr.2015.11.017
- https://doi.org//10.1158/0008-5472.Can-18-1102
- https://doi.org//10.1016/j.prp.2020.152859
- https://doi.org//10.1016/j.urolonc.2017.06.004
- https://doi.org//10.1039/d0sc00317d
- https://doi.org//10.1016/j.molmed.2014.02.007
- https://doi.org//10.1038/s41389-019-0179-2
CC BY 4.0